Analysts Set Abivax SA Sponsored ADR (NASDAQ:ABVX) PT at $156.50

Abivax SA Sponsored ADR (NASDAQ:ABVX) has received a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $156.50.

A number of brokerages recently weighed in on ABVX. Wolfe Research set a $136.00 target price on shares of Abivax in a research report on Wednesday, June 3rd. Leerink Partners lifted their price target on shares of Abivax from $140.00 to $148.00 and gave the company an “outperform” rating in a report on Tuesday, June 30th. Morgan Stanley reiterated an “overweight” rating and issued a $180.00 price target on shares of Abivax in a research note on Friday, July 24th. HC Wainwright reissued a “buy” rating on shares of Abivax in a report on Tuesday, June 30th. Finally, Wedbush raised their price objective on Abivax from $90.00 to $110.00 and gave the company a “neutral” rating in a research report on Tuesday, June 30th.

Hedge Funds Weigh In On Abivax

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. increased its stake in Abivax by 155.6% in the 1st quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock worth $26,000 after acquiring an additional 140 shares during the last quarter. Versant Capital Management Inc purchased a new stake in shares of Abivax during the 2nd quarter worth approximately $30,000. Bank of America Corp DE boosted its position in shares of Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after acquiring an additional 1,990 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Abivax by 661.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after acquiring an additional 344 shares during the last quarter. Finally, WPG Advisers LLC grew its holdings in shares of Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after purchasing an additional 253 shares in the last quarter. 47.91% of the stock is owned by institutional investors.

Abivax Trading Up 0.3%

NASDAQ ABVX opened at $125.19 on Friday. Abivax has a 12 month low of $67.09 and a 12 month high of $148.83. The stock has a market cap of $10.92 billion, a PE ratio of -24.03 and a beta of 1.03. The stock’s 50 day moving average is $118.57 and its 200 day moving average is $118.45.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $0.40 million. On average, analysts forecast that Abivax will post -3.22 EPS for the current fiscal year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.